Do you want fast-track trade mark examination?

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Do you want fast-track trade mark examination?

The UK IPO is again asking users whether they would make use of fast-track trade mark examination

Speedy filing, on payment of a higher fee, was one of the recommendations made by the Gowers Review in 2006. Following a consultation, it was introduced in the UK in 2008.

But take up was low, and the standard procedure became quicker, leading to the service being suspended in 2009.

In 2012, then IP minister Lord Marland proposed reintroducing the fast track. Since then, standard examining times have continued to fall.

The IPO says that now is “an appropriate time to consult on the need, and demand, for the reintroduction of the service”.

A PDF document sets out the full details of the consultation, including specific questions regarding use of the fast-track procedure. These include: Would you make use of a fast track procedure at 5 days for £300? And What would you consider to be an optimum period for receiving the first examination report?

Responses from any interested party can be sent to the IPO by email.

more from across site and SHARED ros bottom lb

More from across our site

Julia Bishop is director of IP at Twilio in the US
Hellberg is an IP director at Essity in Sweden
Teemu Itälä is head of legal and compliance for technology standards at Nokia in Finland
Palińska is the business & IP law lead at CD Projekt Red in Poland
Schwitulla is the head of litigation management at Nokia in Germany
David Degen is senior IP counsel at Novartis, Switzerland
Demetrio Roberto Cavicchia is an IP director at Angelini Pharma in Italy
Almeida is the IP group leader at Bosch in Brazil
Amanda Luz is brand protection manager - global at Adidas in the US
Samantak Ghosh is vice president of IP at Avere Therapeutics in the US
Gift this article